SCHEMBL8469211

SCHEMBL8469211

CC(C)Oc1cccc(-c2ccccc2)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.72
RXRB P28702 1/20 0.72
GABRA1 P14867 1/20 0.64
GABRG2 P18507 1/20 0.64
GABRB3 P28472 1/20 0.64
GABRA5 P31644 1/20 0.64
GABRA3 P34903 1/20 0.64
PTPN5 P54829 1/20 0.59
FFAR4 Q5NUL3 3/20 0.56
MAOA P21397 1/20 0.53
MAOB P27338 1/20 0.53
SLC13A5 Q86YT5 1/20 0.51
CNR1 P21554 1/20 0.50
CYP1A2 P05177 1/20 0.47
GAA P10253 1/20 0.47
CYP2C9 P11712 1/20 0.47
PKM P14618 1/20 0.47
CYP2C19 P33261 1/20 0.47
MAPT P10636 2/20 0.47
ATM Q13315 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14303566 0.86 RXRA (0.66) RXRARXRBGABRA1GABRG2GABRB3
SCHEMBL534096 0.85 RXRA (0.59) RXRARXRBGABRA1GABRG2GABRB3
SCHEMBL8470898 0.85 RXRA (0.64) RXRARXRBGABRA1GABRG2GABRB3
SCHEMBL8524895 0.85 RXRA (0.69) RXRARXRBGABRA1GABRG2GABRB3
SCHEMBL18210776 0.84 RXRA (0.58) RXRARXRBGABRA1GABRG2GABRB3
SCHEMBL20557906 0.82 RXRA (0.57) RXRARXRBGABRA1GABRG2GABRB3
SCHEMBL30469319 0.82 RXRA (0.57) RXRARXRBGABRA1GABRG2GABRB3
SCHEMBL13376511 0.82 RXRA (0.57) RXRARXRBGABRA1GABRG2GABRB3
SCHEMBL2567825 0.82 RXRA (0.60) RXRARXRBGABRA1GABRG2GABRB3
SCHEMBL2968363 0.82 RXRA (0.53) RXRARXRBGABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1999025707-A1 2-ARYLBENZO[b]THIOPHENES USEFUL FOR THE TREATMENT OF ESTROGEN DEPRIVATION SYNDROME ELI LILLY AND COMPANY (US) 1999-05-27 WO claimed
US-20230276692-A1 LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2023-08-31 US disclosed
US-20100102710-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-04-29 US disclosed
US-20100102710-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-04-29 US disclosed
US-20090295281-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-12-03 US disclosed
US-20090295281-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-12-03 US disclosed
US-20090261714-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-10-22 US disclosed
US-20090252990-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-10-08 US disclosed
US-20090252990-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-10-08 US disclosed
US-20090189520-A1 Novel red electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-07-30 US disclosed
US-20090159130-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-06-25 US disclosed
US-20090159130-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-06-25 US disclosed
US-20090153037-A1 Novel red electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-06-18 US disclosed
US-20090145483-A1 Novel electroluminescent compounds and organic electroluminescent device suing the same GRACEL DISPLAY INC. (KR) 2009-06-11 US disclosed
US-20090078317-A1 Organometalic compounds for electroluminescence and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-03-26 US disclosed
US-20070191380-A1 KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION IRM LLC (BM) 2007-08-16 US disclosed
US-20070191380-A1 KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION IRM LLC (BM) 2007-08-16 US disclosed
US-7238714-B2 Aryl or heteroaryl amide compounds PFIZER JAPAN, INC. (JP) 2007-07-03 US disclosed
US-7176312-B2 Kinase inhibitor scaffolds and methods for their preparation THE SCRIPPS RESEARCH INSTITUTE (US) 2007-02-13 US disclosed
WO-1999025707-A1 2-ARYLBENZO[b]THIOPHENES USEFUL FOR THE TREATMENT OF ESTROGEN DEPRIVATION SYNDROME ELI LILLY AND COMPANY (US) 1999-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090145483-A1 Novel electroluminescent compounds and organic electroluminescent device suing the same LEF1, ODC1, AOC2 RXRA 4359/4885RXRB 4205/4885GABRA1 2781/4885
US-20090261714-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same AOX1, ODC1, LEF1 RXRA 4177/4885RXRB 4076/4885GABRA1 3315/4885
US-20090078317-A1 Organometalic compounds for electroluminescence and organic electroluminescent device using the same OCIAD1, L1CAM, OCIAD2 RXRA 3507/4885RXRB 2985/4885GABRA1 4655/4885
US-20090252990-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same AOX1, LEF1, ODC1 RXRA 4081/4885RXRB 4043/4885GABRA1 3200/4885
US-20090153037-A1 Novel red electroluminescent compounds and organic electroluminescent device using the same NDUFS2, ALDH1A2, ODC1 RXRA 2485/4885RXRB 2577/4885GABRA1 3507/4885
US-20090295281-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same AOX1, LEF1, ODC1 RXRA 4282/4885RXRB 4257/4885GABRA1 3597/4885
US-20100102710-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ODC1, AOX1, OR10J3 RXRA 4232/4885RXRB 4133/4885GABRA1 3095/4885
US-20090159130-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same AOX1, LEF1, ODC1 RXRA 4081/4885RXRB 4043/4885GABRA1 3200/4885
US-20070191380-A1 KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION MAP2K2, MAP2K1, MAP2K7 RXRA 3981/4885RXRB 4056/4885GABRA1 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.